Search research articles
Contact Us
Filters
Showing results (121-130 of 167) with videos related to
Page
of 17
Sort By:
The Oncologist
|
December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer
Margaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
Nature Communications
|
February 20, 2024
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Anwaar Saeed, Robin Park, Harsh Pathak, et al.
NPJ Precision Oncology
|
February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer
Ibrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Lancet (London, England)
|
October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
J Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
Future Oncology (London, England)
|
March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)
Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
The Oncologist
|
June 6, 2026
Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC)
Anup Kasi, Raed Moh'd Taiseer Al-Rajabi, Joaquina Celebre Baranda, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial
Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.
The Lancet. Oncology
|
October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Journal for Immunotherapy of Cancer
|
June 16, 2022
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Brett Marinelli, Edward Kim, Antonio D'Alessio, et al.
Cancers
|
October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
Khalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 167) with videos related to
Sort By:
Page
of 17
The Oncologist
|
December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer
Margaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
Nature Communications
|
February 20, 2024
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Anwaar Saeed, Robin Park, Harsh Pathak, et al.
NPJ Precision Oncology
|
February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer
Ibrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Lancet (London, England)
|
October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
J Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
Future Oncology (London, England)
|
March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)
Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
The Oncologist
|
June 6, 2026
Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC)
Anup Kasi, Raed Moh'd Taiseer Al-Rajabi, Joaquina Celebre Baranda, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial
Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.
The Lancet. Oncology
|
October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Journal for Immunotherapy of Cancer
|
June 16, 2022
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Brett Marinelli, Edward Kim, Antonio D'Alessio, et al.
Cancers
|
October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
Khalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Page
of 17